Our Science

 Ir-Vax therapy for early breast or any other cancer has the potential to make the disease disappear entirely in a substantial proportion of subjects in the 4-6 weeks prior to scheduled surgery.

T-cells don’t naturally recognize tumor-specific proteins on the surface of cancer cells due to the cloaking ability of cancer.  Tumor cells are seen as “self” by our immune system, which partly explains the success of cancer as a disease.

Dendritic cells (DCs) are antigen-presenting cells (also known as accessory cells) of the mammalian immune system. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. This is how our bodies routinely eliminate microbial threats.

The rationale for use of Dendritic Cells (DC1) as immunotherapeutic vehicles derives from their role as the master Antigen Presenting Cell (APC) of the immune system13.  Consequently, they can be directed to induce an immunologic response directed at a specific antigen (Ag). This response is therefore potentially much more tumor-specific than the more general immune activation induced by checkpoint inhibitors or cytokines. As a result, the toxicity profile of vaccines has been demonstrably less than that for cytokines or checkpoint inhibitors12.

ImmunoRestoration’s core technology (Immune Conditioning via Activated Innate (autologous) Transfer - ICAIT©) is a novel, integrated dendritic cell-based immunization system to overcome some of the known obstacles facing anti-cancer vaccines:  Breakthrough finding: HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact both invasive breast cancer as well as ductal carcinoma in situ.

The Ir-Vax is specifically designed to mimic the natural process of microbial elimination and direct it instead against cancer.

Greater than 100 patients have been treated with Ir-Vax since 2004 and in addition to complete responders, there is a strong apparent suppression of disease recurrence in treated patients.